Allograft
Conditions
Keywords
Allograft, Cytomegalovirus, Platelets, Hematopoietic stem cells, Graft Versus Host Disease (GVH), Hemostasis, Adaptive immunity, Innate immunity, Post graft follow up
Brief summary
Traditionally known for their role in haemostasis, platelets have also an immune role. Platelets play a key role in immune mediator secretion, and interact with innate and adaptive immune cells, contributing to the fight against pathogens, as viruses. Cytomegalovirus (CMV) is responsible of allograft patients' serious infections, because of the induced immune depression. Platelets activation for patients is not determined during the post-graft period, and platelet induced inflammation following a CMV infection is not described.
Detailed description
The descriptive present study will determine if platelet activation is altered during the post-graft follow-up (day 30 to 90). The activation will be studied spontaneously and after simulation by a CMV (Cytomegalovirus) antigen. The study will also focus on inflammatory response variation, focusing on the cytokines release during the same post-graft follow-up (spontaneously and after CMV antigen stimulation). This preliminary study could lead to a better understanding of the immune-modulator role of inflammation, controlled by the platelets, particularly in the initiation of the Graft-versus-host disease in this kind of population.
Interventions
OTHERBlood samples
Two blood tubes will be collected each week during 8 weeks maximum for the present study. Samples will start at day 30 post-graft and finish at day 90 post-graft maximum.
Sponsors
Groupe sur l'Immunité des Muqueuses et Agents Pathogènes, (GIMAP)
Association Stéphanoise Pour la Recherche en Hématologie-Oncologie (ASPHRO)
Institut de Cancérologie de la Loire
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Patients who received an allogeneic haematopoietic stem cell transplant for less than 2 months for any indication ; * Platelets \> 20 G / L (Giga per Litre) for at least 7 days without transfusion support ; * Patients affiliated to a social security scheme.
Exclusion criteria
* Patients receiving antiplatelet therapy ; * Major protected or unable to give consent ; * Pregnant women ; * Vulnerable persons defined by French legislation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| In vitro CD63 (membrane protein) expression level after a CMV antigen stimulation | 90 Days | In vitro CD63 (membrane protein) expression level will be calculated after a CMV antigen stimulation, and will reflect platelet activation for Hematopoietic stem cells allograft patients during their follow up. |
| In vitro spontaneous CD62P (P-selectin) expression level | 90 Days | In vitro spontaneous CD62P (P-selectin) expression level will be calculated, and will reflect platelet activation for Hematopoietic stem cells allograft patients during their follow up. |
| In vitro spontaneous CD63 (membrane protein) expression level | 90 Days | In vitro spontaneous CD63 (membrane protein) expression level will be calculated, and will reflect platelet activation for Hematopoietic stem cells allograft patients during their follow up. |
| In vitro CD62P (P-selectin) expression level after a CMV antigen stimulation | 90 Days | In vitro CD62P (P-selectin) expression level will be calculated after a CMV antigen stimulation, and will reflect platelet activation for Hematopoietic stem cells allograft patients during their follow up. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Level of in vitro spontaneous platelet activation | 90 Days | Level of in vitro spontaneous platelet activation for Hematopoietic stem cells allograft patients during their follow up. The level is calculated with PF4 (Recombinant Platelet Factor 4), RANTES (Chemokine (C-C motif) ligand 5), soluble CD40L (CD 40 ligand), MIP1alpha (Macrophage Inflammatory Proteins), sCD62P (soluble p-selectin) spontaneous expression level. |
| Level of in vitro platelet activation after a CMV antigen stimulation | 90 Days | Level of in vitro platelet activation after a CMV antigen stimulation for Hematopoietic stem cells allograft patients during their follow up. The level is calculated with PF4 (Recombinant Platelet Factor 4), RANTES (Chemokine (C-C motif) ligand 5), soluble CD40L (CD 40 ligand), MIP1alpha (Macrophage Inflammatory Proteins), sCD62P (soluble p-selectin) expression level. |
Countries
France
Outcome results
None listed